Allied-Market-Research-mobile

Coming Up With New Logo

Cart
0
Get 20% Free Customization In This Report

STD Testing Market (Sexually Transmitted Diseases Testing) By Sexually Transmitted Disease Types (Chlamydia testing, Syphilis, Gonorrhoea, Herpes Simplex Virus, Human Papilloma Virus, Human Immunodeficiency Virus testing) and Testing Devices ( Thermal Cyclers - PCR, Lateral Flow Readers - Immunochromatographic assays, Flow Cytometers, Differential Light Scattering machines, Absorbance microplate reader, Phone chips, rapid diagnostic kits) - Global Opportunity Analysis and Industry Forecast, 2013 - 2020

  • ID: LI 14385
  • Nov 2014
  • 110 pages
  • Price: $4296
$2765

STD Testing Market Overview:

STD Testing Market (Sexually Transmitted Diseases Testing Market) is expected to garner $167.4 billion by 2020, registering a CAGR of 8.5% during the forecast period 2014-2020.

STDs are a grave issue globally, and are responsible for high morbidity in adults and cause infertility in both men and women. Complications such as ectopic pregnancy, cervical cancer in women and congenital mortality are observed in patients suffering from STDs. Generally, patients suffering from STDs are observed to be within 15 to 44 years, and ~500 million new cases of STDs are registered per year. Diagnostic procedures of STDs market include the technologies that are used to identify and analyze STD along with the laboratories where the tests are carried out.

The global STD testing market based on the disease type is segmented into chlamydia testing, syphilis testing, gonorrhoea testing, herpes simplex virus testing, human papilloma virus testing, human immunodeficiency virus testing, and chancroid testing. Based on location of testing the global STD testing market is segmented into laboratory testing, and point of care (PoC) testing. This report includes variety of diagnostic testing techniques that are used in identifying the infectious diseases. Some of the popular tests such as blood or serum testing and PCR testing are considered during estimations. This report considers the revenue from the private as well as publicly funded STD programs. This report excludes the revenue generated from the devices sold in the market. STD devices have been estimated according to the type of devices used during testing.

Sexually Transmitted Diseases Testing Market

Diagnostic testing programs are implemented by health care departments in developed regions for prevention and control of transmission, specifically of P&S Syphilis, Chlamydia, Gonorrhea and HPV. Provisions for diagnostic tests and technologies for STDs should comply with stringent regulations. On compliance with the norms and gaining accreditation from authorities, companies developing and supplying laboratory STD diagnostic tests will be eligible for contracts for nation-wide testing volume provision and result in benefits for the market participants. Additionally, if accreditation and regulatory approvals are obtained, the POC testing/technologies and kits/chips providers can qualify to participate in national screening programs in developing regions.

The associated social stigma has led many STD infected individuals to refrain from testing in specialized STD clinics and Genito-Urinary Medicine (GUM) clinics that is anticipated to hamper the STD testing market growth. On the contrast, historically, it has been observed that visits to generalize public and private labs for STD testing has increased as against specialized STD clinics. Thus, it is likely to be economic and beneficial for companies providing new STD diagnostic tests/technologies and laboratory equipment and supplies to public and private labs. The change in the consumer (STD infected and individuals opting for voluntary/CICT testing) buying behavior is thus beneficial for public or private labs and they can aim to increase the supply of STD diagnostic testing services, i.e. expanding business horizons. This is set to supplement the growth of STD testing market in near future.

The increasing prevalence and incidence of STDs will increase the demand for diagnostic testing of STDs. However, a there are factors that are likely to restrain the STD testing market growth. It is estimated that the impact of the drivers is likely to be higher than the restraints; the global STD testing market is likely to grow at CAGR of 8.5% during the forecast period. Additionally, a cumulative effect of the drivers and the restraints is likely to reveal few niche market opportunities that can be capitalized by companies supplying STD diagnostic tests, supplies and equipment providers and public and private labs proving beneficial for the expansion of STD testing market at a global level.

The French disease” or “The Great Pox” was referred to P&S Syphilis infections that were more prevalent in France in 14th century. Later, this disease was entirely spread across North America and Europe. Syphilis disease specifically consists of three stages that include primary, secondary and latent or late stage. Highly contagious and asymptomatic nature of Syphilis leads to undetected progression until the later stage. The disease could clinically manifest to 10 years, after original infection. Moreover, if it is left untreated in the later stages, complications could be serious or sometimes lethal for the patients. This has created awareness among people regarding the importance of immediate diagnosis of sexually transmitted diseases that has further propelled the growth of STD testing market.

Asia-Pacific and LAMEA regions have exhibited higher prevalence and incidence rates of HIV, P&S Syphilis, HSV and Chancroid. These regions are considered poor in supply-side infrastructure due to insufficient laboratories, clinics and set-ups where STD testing is carried out. Such labs and testing centers are out of reach for patients and people opting for CICT/PICT testing. Low buying power and unfavorable reimbursement rates for testing of STDs are responsible for rising prevalence and incidence rates. The aforementioned factors contribute to the robust growth displayed by Asia-Pacific region in the STD testing market followed by LAMEA.

However, considering the large market size (resulting from a larger cohort of the targeted population aged 15 - 44 years); will be profitable for STD testing market participants. The companies developing and supplying POC tests, as POC tests are easily available in out-of-reach areas and are cost effective, so many companies are targeting for screening programs for HIV and P&S Syphilis testing.

KEY BENEFITS

  • The analysis helps in understanding the strategies adopted by various companies for gaining market share in the market for diagnostic testing of STDs
  • The report provides comprehensive analysis of factors that drive and restrict the growth of the market for diagnostic testing of STDs.
  • Market conditions of STD diagnostic testing market across all geographic regions are comprehensively analyzed. Key trends such as national and voluntary screening programs within regional markets, for example, European markets are expected to drive growth of the market.
  • Prime focus of the report is opportunity-analysis within this market. STD infected individuals refrain from testing in specialized STD clinics and Genito-Urinary Medicine (GUM) clinics due to the associated social stigma. Such change in the consumer buying behavior would prove to be an opportunity and be beneficial for public and private labs.

SEXUALLY TRANSMITTED  DISEASES (STDS) TESTING MARKET SEGMENTATION

The diagnostic testing of STDs market is segmented into types of STDs tested, testing devices, laboratory testing, PoC testing and geography.

By Sexually Transmitted Disease Types

  • Chlamydia testing
  • Syphilis testing
  • Gonorrhoea testing
  • Herpes Simplex Virus testing
  • Human Papilloma Virus testing
  • Human Immunodeficiency Virus testing
  • Chancroid testing

By Location Of Testing

  • Laboratory Testing
    • Commercial/Private labs
    • Public Health Labs
  • Point of Care (PoC) testing

By Testing Devices

  • Laboratory Devices: Instruments and systems
    • Thermal Cyclers - PCR
    • Lateral Flow Readers - Immunochromatographic assays
    • Flow Cytometers
    • Differential Light Scattering machines
    • Absorbance microplate reader - Enzyme Linked Immunosorbent Assay (ELISA)
  • POC testing Devices: Various diagnostic kits
    • Phone chips (microfluidics + ICT)
    • Portable / bench top / rapid diagnostic kits

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America, Middle East, Africa (LAMEA)
 

Chapter: 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO perspective
2.2 Market beyond what to expect by 2025 ($ Million)

2.2.1 Base case scenario
2.2.2 Optimistic scenario
2.2.3 Critical scenario

Chapter: 3 MARKET OVERVIEW

3.1 Market Definition and Scope
3.2 Upcoming trends for STDs diagnostic testing market
3.3 Technological Advancements for STDs diagnostic testing market
3.4 Emerging economies as a beneficial criterion for the investors

3.4.1 Top Factors Impacting for STDs diagnostic testing market
3.4.3 Top winning strategies for STDs diagnostic testing market

3.5 Different types of diagnostic tests of STDs
3.6 Government Regulations and reimbursement

3.6.1 California codes with different Laws related to STD control
3.6.2 Reimbursement policies for STD testing

3.7 Value chain analysis of STD testing devices market

3.7.1 Source: AMR Analysis Primary Activities
3.7.2 Supportive Activities

3.8 Market Dynamics

3.8.1 Drivers

3.8.1.1 Growing incidence rates and increasing prevalence rates of STD
3.8.1.2 Implementation of National Screening Programs
3.8.1.3 Supporting Reimbursement for STDs testing

3.8.2 Restraints

3.8.2.1 Social stigma associated with patients visiting specialized STD clinics.
3.8.2.2 Huge proportion of patients infected with STDs in out-of-reach geographic areas.
3.8.2.3 Stringent regulatory abidance requirements for the participants of std market

3.8.3 Opportunities

3.8.3.1 Decreasing number of visits to GUM clinics and specialized STD clinics
3.8.3.2 National screening Programs across the globe
3.8.3.3 Niche opportunities for technology and POC test providers in an emerging economies

Chapter: 4 GLOBAL STDS DIAGNOSTIC TESTING MARKET BY DISEASE TYPE

4.1 Chlamydia testing (volume and value)

4.1.1 Key market trends
4.1.2 Market size and forecast

4.1.2.1 Global Testing Market for Chlamydia, volume
4.1.2.2 Global Testing Market for Chlamydia, Value

4.2 P&S Syphilis testing (volume and value)

4.2.1 Key market trends
4.2.2 Market size and forecast

4.2.2.1 Global Testing Market for P&S Syphilis, volume
4.2.2.2 Global Testing Market for P&S Syphilis,value

4.2.3 Global P&S syphilis testing market, by Region

4.2.3.1 Europe

4.2.3.1.1 SPAIN
4.2.3.1.2 GREECE

4.2.3.2 All Other Europe
4.2.3.3 LAMEA

4.2.3.3.1 LATIN AMERICA
4.2.3.3.2 ARGENTINA
4.2.3.3.3 MIDDLE EAST
4.2.3.3.4 AFRICA

4.2.4 Global P&S Syphilis testing Market, By Type

4.2.4.1 Primary Syphilis
4.2.4.2 Secondary Syphilis

4.3 Gonorrhea testing (volume and value)

4.3.1 Key market trends
4.3.2 Market size and forecast

4.3.2.1 Global Testing Market for Gonorrhea,volume
4.3.2.2 Global Testing Market for Gonorrhea,value

4.4 Herpes Simplex Virus (HSV) testing (volume and value)

4.4.1 Key market trends
4.4.2 Market size and forecast

4.4.2.1 Global Testing Market for HSV,volume
4.4.2.2 Global Testing Market for HSV,value

4.5 Human Papilloma Virus (HPV) testing (volume and value)

4.5.1 Key market trends
4.5.2 Market size and forecast

4.5.2.1 Global Testing Market for HPV,volume
4.5.2.2 Global Testing Market for HPV,value

4.6 Human Immunodeficiency Virus (HIV) testing (volume and value)

4.6.1 Key market trends
4.6.2 Market size and forecast

4.6.2.1 Global Testing Market for HiV,volume
4.6.2.2 Global Testing Market for HiV,value

4.7 Chancroid testing (volume and value)

4.7.1 Key market trends
4.7.2 Market size and forecast

4.7.2.1 Global Testing Market for Chancroid,volume
4.7.2.2 Global Testing Market for Chancroid,value

Chapter: 5 GLOBAL STDS DIAGNOSTIC TESTING MARKET BY LOCATION OF TESTING

5.1 Market size and forecast
5.2 Laboratory testing

5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Commercial laboratory testing
5.2.4 Private laboratory testing
5.2.5 Public laboratory testing
5.2.6 Key market trends
5.2.7 Key growth factors and opportunities

5.3 Point of care testing

5.3.1 Key market trends
5.3.2 Key growth factors and opportunities

Chapter: 6 GLOBAL STDS DIAGNOSTIC TESTING MARKET BY TESTING DEVICES

6.1 Market size and forecast
6.2 Laboratory Testing Devices

6.2.1 PCRs
6.2.2 Immunochromatographic capillary flow dipstick technology (Assay)
6.2.3 Flow Cytometers
6.2.4 Differential Light Scattering
6.2.5 Enzyme Linked Immunosorbent Assay (ELISA)

6.3 Point of Care Testing Devices

6.3.1 Phone Chips
6.3.2 Microfluidics
6.3.3 Immunochromatographic Tests (ICTs)
6.3.4 Rapid diagnostic kits

Chapter: 7 GLOBAL STDS DIAGNOSTIC TESTING MARKET BY GEOGRAPHY

7.1 North America
7.2 Europe
7.3 Asia Pacific
7.4 LAMEA

7.4.1 LAMEA STD testing market by disease type (value and Volume), 2013-2020

7.4.1.1 LAMEA Chlamydia testing market by region, (volume & value), 2013-2020

7.4.1.1.1 LATIN AMERICA
7.4.1.1.2 MIDDLE EAST
7.4.1.1.3 SOUTH AFRICA
7.4.1.1.4 OTHER AFRICAN COUNTRIES

7.4.1.2 LAMEA P&S Syphilis testing market by region, (volume & value), 2013-2020

7.4.1.2.1 LATIN AMERICA
7.4.1.2.2 MIDDLE EAST
7.4.1.2.3 SOUTH AFRICA
7.4.1.2.4 OTHER AFRICAN COUNTRIES

7.4.1.3 LAMEA Gonorrhea testing market by region, (volume & value), 2013-2020

7.4.1.3.1 LATIN AMERICA
7.4.1.3.2 MIDDLE EAST
7.4.1.3.3 SOUTH AFRICA
7.4.1.3.4 OTHER AFRICAN COUNTRIES

7.4.1.4 LAMEA Herpes Simplex Virus testing market by region, (volume & value), 2013-2020

7.4.1.4.1 LATIN AMERICA
7.4.1.4.2 MIDDLE EAST
7.4.1.4.3 SOUTH AFRICA
7.4.1.4.4 OTHER AFRICAN COUNTRIES

7.4.1.5 LAMEA Human Papilloma Virus testing market by region, (volume & value), 2013-2020

7.4.1.5.1 LATIN AMERICA
7.4.1.5.2 MIDDLE EAST
7.4.1.5.3 SOUTH AFRICA
7.4.1.5.4 OTHER AFRICAN COUNTRIES

7.4.1.6 LAMEA Human Immunodeficiency Virus testing market by region, (volume & value), 2013-2020

7.4.1.6.1 LATIN AMERICA
7.4.1.6.2 MIDDLE EAST
7.4.1.6.3 SOUTH AFRICA
7.4.1.6.4 OTHER AFRICAN COUNTRIES

7.4.1.7 LAMEA Chancroid testing market by region, (volume & value), 2013-2020

7.4.1.7.1 LATIN AMERICA
7.4.1.7.2 MIDDLE EAST
7.4.1.7.3 SOUTH AFRICA
7.4.1.7.4 OTHER AFRICAN COUNTRIES

Chapter: 8 COMPANY PROFILES

8.1 Roche Diagnostics

8.1.1 Company overview
8.1.2 Operating business segments
8.1.3 Financial performance
8.1.4 Strategic moves and developments
8.1.5 SWOT analysis Roche Diagnostics

8.2 Biomerieux

8.2.1 Company overview
8.2.2 Operating business segments
8.2.3 Business performance
8.2.4 SWOT analysis of BioMerieux

8.3 Hologic, Inc.

8.3.1 Company overview
8.3.2 Operating business segments
8.3.3 Financial performance
8.3.4 Strategic moves and developments
8.3.5 SWOT analysis of Hologic Inc

8.4 Becton Dickinson And Company

8.4.1 Company overview
8.4.2 Operating Business Segments
8.4.3 Business performance
8.4.4 Key Strategies and development
8.4.5 SWOT analysis of Becton Dickinson and Company

8.5 Cepheid Inc.

8.5.1 Company overview
8.5.2 Operating Business Segments
8.5.3 Financial performance
8.5.4 Strategic moves and developments
8.5.5 SWOT analysis of Cepheids

8.6 Danaher Corporation

8.6.1 Company overview
8.6.2 Operating business segments
8.6.3 Business performance
8.6.4 Key Strategies and development
8.6.5 SWOT analysis of Danaher Corporation

8.7 Affymetrix, Inc.

8.7.1 Company overview
8.7.2 Operating. business segments
8.7.3 Financial performance
8.7.4 SWOT analysis of Affymetrix Inc

8.8 Alere Inc.

8.8.1 Company overview
8.8.2 Operating business segments
8.8.3 Business performance
8.8.4 Key Strategies and developments
8.8.5 SWOT analysis of Alere Inc.

8.9 Abbott Laboratories

8.9.1 Company overview
8.9.2 Operating business segments
8.9.3 Financial performance
8.9.4 Strategic moves and developments
8.9.5 SWOT analysis of Abbotts

8.10 DiaSorin

8.10.1 Company overview
8.10.2 Operating business segments
8.10.3 Financial performance
8.10.4 Strategic moves and developments
8.10.5 SWOT analysis of DiaSorin

LIST OF TABLES

TABLE 1 GLOBAL STD DIAGNOSTIC TESTING MARKET, MODERATE GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 2 GLOBAL STD DIAGNOSTIC TESTING MARKET, RAPID GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 3 GLOBAL STD DIAGNOSTIC TESTING MARKET, DIMINISHING GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 4 STD PREVENTIVE SERVICES BY CDC
TABLE 5 GLOBAL STD TESTING MARKET REVENUE, BY DISEASE TYPE, 2013-2020 ($MILLION)
TABLE 6 GLOBAL STD TESTING MARKET VOLUME, BY DISEASE TYPE, 2013-2020 (IN MILLION)
TABLE 7 GLOBAL CHLAMYDIA TESTING MARKET VOLUME, BY GEOGRAPHY, 2013-2020 (IN MILLION)
TABLE 8 GLOBAL CHLAMYDIA TESTING MARKET REVENUE, BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 9 GLOBAL P&S SYPHILIS TESTING MARKET VOLUME, BY GEOGRAPHY, 2013-2020 (IN MILLION)
TABLE 10 GLOBAL P&S SYPHILIS TESTING MARKET REVENUE, BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 11 EUROPE P&S SYPHILIS TESTING MARKET BY VALUE ($MILLION), 2013-2020
TABLE 12 EUROPE P&S SYPHILIS TESTING MARKET BY VOLUME (MILLION), 2013-2020
TABLE 13 SPAIN P&S SYPHILIS TESTING MARKET VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 14 GREECE P&S SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 15 OTHERS EUROPE P&S SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 16 LAMEA P&S SYPHILIS TESTING MARKET BY VALUE, ($MILLION), 2013-2020
TABLE 17 LAMEA P&S SYPHILIS TESTING MARKET BY VOLUME (MILLION), 2013-2020
TABLE 18 LATIN AMERICA P&S SYPHILIS TESTING MARKET BY VALUE ($MILLION), 2013-2020
TABLE 19 LATIN AMERICA P&S SYPHILIS TESTING MARKET BY VOLUME (MILLION), 2013-2020
TABLE 20 ARGENTINA P&S SYPHILIS TESTING MARKET , VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 21 MIDDLE EAST P&S SYPHILIS TESTING MARKET VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 22 AFRICA P&S SYPHILIS TESTING MARKET BY VALUE ($MILLION), 2013-2020
TABLE 23 AFRICA P&S SYPHILIS TESTING MARKET BY VOLUME (MILLION), 2013-2020
TABLE 24 GLOBAL P&S SYPHILIS TESTING MARKET BY VALUE ($MILLION), 2013-2020
TABLE 25 GLOBAL P&S SYPHILIS TESTING MARKET BY VOLUME (MILLION), 2013-2020
TABLE 26 PERCENTAGE FOR TOTAL NUMBER OF CASES OF GONORRHEA RESISTANCE (%)
TABLE 27 GLOBAL GONORRHEA TESTING MARKET VOLUME, BY GEOGRAPHY, 2013-2020 (IN MILLION)
TABLE 28 GLOBAL GONORRHEA TESTING MARKET REVENUE, BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 29 GLOBAL HSV TESTING MARKET VOLUME, BY GEOGRAPHY, 2013-2020 (IN MILLION)
TABLE 30 GLOBAL HSV TESTING MARKET REVENUE, BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 31 GLOBAL HPV TESTING MARKET VOLUME, BY GEOGRAPHY, 2013-2020 (IN MILLION)
TABLE 32 GLOBAL HPV TESTING MARKET REVENUE, BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 33 GLOBAL HIV TESTING MARKET VOLUME, BY GEOGRAPHY, 2013-2020 (IN MILLION)
TABLE 34 GLOBAL HIV TESTING MARKET REVENUE, BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 35 GLOBAL CHANCROID TESTING MARKET VOLUME, BY GEOGRAPHY, 2013-2020 (IN MILLION)
TABLE 36 GLOBAL CHANCROID TESTING MARKET REVENUE, BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 37 GLOBAL STDS TESTING MARKET REVENUE, BY LOCATION OF TESTING SERVICES, 2013-2020 ($ MILLION)
TABLE 38 GLOBAL STD DIAGNOSTIC TESTING MARKET BY TESTING DEVICES, 2013-2020, $ MILLION
TABLE 39 TESTING TECHNOLOGIES FOR STDS
TABLE 40 SEROLOGICAL TEST FOR STDS
TABLE 41 GLOBAL STDS DIAGNOSTICS TESTING MARKET, BY GEOGRAPHY, 2013 - 2020 ($ MILLION)
TABLE 42 GLOBAL STDS DIAGNOSTICS TESTING MARKET, BY GEOGRAPHY, 2013 - 2020 ($ MILLION)
TABLE 43 NORTH AMERICA STDS DIAGNOSTICS TESTING MARKET, BY DISEASE TYPE, 2013-2020, ($MILLION)
TABLE 44 EUROPE STDS DIAGNOSTICS TESTING MARKET, BY DISEASE TYPE, 2013-2020, ($MILLION)
TABLE 45 ASIA PACIFIC STDS DIAGNOSTICS TESTING MARKET, BY DISEASE TYPE, 2013-2020, ($MILLION)
TABLE 46 LAMEA STDS DIAGNOSTICS TESTING MARKET, BY DISEASE TYPE, 2013-2020, ($MILLION)
TABLE 47 LAMEA STDS TESTING MARKET BY VOLUME (MILLION), 2013-2020
TABLE 48 LATIN AMERICA CHLAMYDIA TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 49 MIDDLE EAST CHLAMYDIA TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 50 SOUTH AFRICA CHLAMYDIA TESTING MARKET VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 51 OTHER AFRICAN COUNTRIES CHLAMYDIA TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 52 LATIN AMERICA P&S SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 53 MIDDLE EAST P&S SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 54 SOUTH AFRICA P&S SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 55 OTHER AFRICAN COUNTRIES P&S SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 56 LATIN AMERICA GONORRHOEA TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 57 MIDDLE EAST GONORRHOEA TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 58 SOUTH AFRICA GONORRHOEA TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 59 OTHER AFRICAN COUNTRIES GONORRHOEA TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 60 LATIN AMERICA HSV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 61 MIDDLE EAST HSV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 62 SOUTH AFRICA HSV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 63 OTHER AFRICAN COUNTRIES HSV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 64 LATIN AMERICA HPV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 65 MIDDLE EAST HPV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 66 SOUTH AFRICA HPV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 67 OTHER AFRICAN COUNTRIES HPV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 68 LATIN AMERICA HIV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 69 MIDDLE EAST HIV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 70 SOUTH AFRICA HIV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 71 OTHERS AFRICAN COUNTRIES HIV TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 72 LATIN AMERICA CHANCROID TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 73 MIDDLE EAST CHANCROID TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 74 SOUTH AFRICA CHANCROID TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 75 OTHER AFRICAN COUNTRIES CHANCROID TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2013-2020
TABLE 76 ROCHE DIAGNOSTICS COMPANY SNAPSHOT
TABLE 77 ROCHE DIAGNOSTICS OPERATING SEGEMENTS
TABLE 78 BIOMERIEUX COMPANY SNAPSHOT
TABLE 79 BIOMERIEUX OPERATING SEGEMENTS
TABLE 80 HOLOGIC, INC. COMPANY SNAPSHOT
TABLE 81 HOLOGIC, INC. OPERATING SEGEMENTS
TABLE 82 BECTON DICKINSON AND COMPANY SNAPSHOT
TABLE 83 BECTON DICKINSON AND COMPANY OPERATING SEGEMENTS
TABLE 84 CEPHIDE INC COMPANY SNAPSHOT
TABLE 85 CEPHEID INC. OPERATING SEGEMENTS
TABLE 86 DANAHER COMPANY SNAPSHOT
TABLE 87 DANAHER CORPORATION OPERATING SEGEMENTS
TABLE 88 AFFYMETRIX INC. COMPANY SNAPSHOT
TABLE 89 AFFYMETRIX, INC. OPERATING SEGEMENTS
TABLE 90 ALERE INC. COMPANY SNAPSHOT
TABLE 91 ALERE INC. OPERATING SEGEMENTS
TABLE 92 ABBOTT LABORATORIES COMPANY SNAPSHOT
TABLE 93 ABBOTT LABORATORIES OPERATING SEGEMENTS
TABLE 94 DANAHER COMPANY SNAPSHOT
TABLE 95 DIASORIN OPERATING SEGEMENTS

LIST OF FIGURES

FIG. 1 IMPACT ANALYSIS OF MODERATE GROWTH SCENARIO (2020-2025)
FIG. 2 IMFPACT ANALYSIS OF RAPID GROWTH SCENARIO (2020-2025)
FIG. 3 IMPACT ANALYSIS OF DIMINISHING GROWTH SCENARIO (2020-2025)
FIG. 4 TOP FACTORS IMPACTING GLOBAL STD MARKET, 2013-2020
FIG. 5 TOP INVESTMENT POCKETS FOR STDS DIAGNOSTICS MARKET (2013-2020)
FIG. 6 TOP WINING STRATEGIES IN GLOBAL STD TESTING MARKET (2011-2014)
FIG. 7 VALUE CHAIN ANALYSIS OF STD DIAGNOSTIC TESTING MARKET
FIG. 8 KEY FINANCIALS OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
FIG. 9 SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIG. 10 KEY FINANCIALS OF BIOMERIEUX BY APPLICATIONS (2013)
FIG. 11 KEY FINANCIALS OF BIOMERIEUX BY GEOGRAPHY (2013)
FIG. 12 SWOT ANALYSIS OF BIOMERIEUX
FIG. 13 KEY FINANCIALS OF HOLOGIC, INC. BY OPERATING SEGMENTS (2012)
FIG. 14 KEY FINANCIALS OF HOLOGIC, INC. BY GEOGRAPHY (2012)
FIG. 15 SWOT ANALYSIS OF HOLOGIC, INC.
FIG. 16 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY BY SEGMENT (2013)
FIG. 17 KEY FINANCIALS OF BECTON DICKINSON AND COMPANY BY GEOGRAPHY (2013)
FIG. 18 SWOT ANALYSIS OF BECTON DICKINSON AND COMPANY
FIG. 19 KEY FINANCIALS OF CEPHEID INC. BY GEOGRAPHY (2013)
FIG. 20 KEY FINANCIALS OF CEPHEID INC. BY CLINICAL AND NON CLINICAL MARKET(2013)
FIG. 21 SWOT ANALYSIS OF CEPHEID INC.
FIG. 22 KEY FINANCIALS OF DANAHER CORPORATION BY OPERATING (SEGMENT) 2013
FIG. 23 KEY FINANCIALS OF DANAHER CORPORATION BY GEOGRAPHY (2013)
FIG. 24 SWOT ANALYSIS OF DANAHER CORPORATION
FIG. 25 KEY FINANCIALS OF AFFYMETRIX, INC. BY OPERATING SEGMENTS (2013)
FIG. 26 KEY FINANCIALS OF AFFYMETRIX, INC. BY GEOGRAPHY (2013)
FIG. 27 SWOT ANALYSIS OF AFFYMETRIX INC.
FIG. 28 KEY FINANCIALS OF ALERE INC. BY OPERATING SEGMENTS (2013)
FIG. 29 KEY FINANCIALS OF ALERE INC. BY GEOGRAPHY (2013)
FIG. 30 SWOT ANALYSIS OF ALERE INC.
FIG. 31 KEY FINANCIALS OF ABBOTT LABORATORIES BY OPERATING SEGMENTS (2013)
FIG. 32 SWOT ANALYSIS OF ABBOTT LABORATORIES
FIG. 33 KEY FINANCIALS OF DIASORIN BY TECHNOLOGY (2013)
FIG. 34 KEY FINANCIALS OF DIASORIN BY GEOGRAPHY (2013)
FIG. 35 SWOT ANALYSIS OF DIASORI

 
 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 

Get More Information About This Report

For any queries about purchasing this report, For any queries, please fill the form below:

Please input the above text in the input box or click refresh

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASK
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Readings

 
 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts